Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
  • C07J1/0003—Androstane derivatives
  • C07J1/0007—Androstane derivatives not substituted in position 17
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

• the present invention relates to a crystalline form of male-3,5?,6?-triol, and to a process for the preparation of a crystalline form of male-3,5?,6?-triol.
• Polymorphism is common in solid drugs. The physical and chemical properties of different crystalline drugs are different. Polymorphism is one of the important factors affecting the efficacy and quality of solid drugs. The solubility of different crystal forms may be several times different. There are large differences in the distribution and metabolism of the body, resulting in differences in bioavailability. In addition, the stability of solid drug substances and their preparations in different crystal forms during preparation and storage Different, crystal transformation will occur, affecting the quality of the drug. Therefore, the phenomenon of drug polymorphism will ultimately affect the quality, efficacy and clinical safety of solid drugs.
• the male -3 ⁇ ,5 ⁇ ,6 ⁇ -triol is a polyhydroxy compound with significant neuroprotective effects.
• the study of polymorphism is important for further study of its efficacy, bioavailability and stability.
• X-ray single crystal diffractometers, X-ray powder diffractometers and differential thermal analyzers have become important methods for quantitative determination of polymorph types, providing more qualitative and quantitative information for solid drug crystal form studies. Summary of the invention
• An object of the present invention is to provide four crystalline compounds of androst-3,5?,6?-triol (hereinafter referred to as YC-6).
• Another object of the present invention is to provide a process for preparing four crystal form compounds of androst-3,5?,6?-triol.
• the present invention provides a crystalline form compound of male-3,5?,6?-triol (hereinafter referred to as twin form YC-6), characterized in that the crystalline form compound is a transparent bulk crystal.
• twin form YC-6 a crystalline form compound of male-3,5?,6?-triol
• the diffraction angles 2 ⁇ are 4.4 ⁇ 0.2, 8.7 ⁇ 0.2, 9.3 ⁇ 0.2, 12.6 ⁇ 0.2, 13.0 ⁇ 0.2, 15.0 ⁇ 0.2, 15.6 ⁇ 0.2, 16.6 ⁇ 0.2, 17.3 ⁇ 0.2, 18.5 ⁇ 0.2, 19.6 ⁇ 0.2 , 21.0 ⁇ 0.2, 21.8 ⁇ 0.2, 24.3 ⁇ 0.2, 27.9 ⁇ 0.2 degrees with diffraction peaks; its endothermic transition
• the temperature is 225 ⁇ 2 °C.
• the method for preparing Form A YC-6 provided by the present invention is: dissolving androst-3 ⁇ ,5 ⁇ ,6 ⁇ -triol in a solvent at room temperature or 50 to 80° C., androst-3 ⁇ , 5 ⁇
• the ratio of 6 ⁇ -triol to solvent is lg: 10 ⁇ 40ml, and then diluted with a solvent, and allowed to stand until crystals are precipitated.
• the solvent for dissolving is acetone, methanol, ethanol, isopropanol, dioxane or tetrahydrofuran;
• the solvent used for dilution is a raw solvent or a poor solvent, wherein the The original solvent is acetone, methanol, ethanol, isopropanol or dioxane (excluding tetrahydrofuran), and the dilution ratio is 0 to 5 times;
• the poor solvent is water, and the dilution ratio is 0 to 2 times.
• the present invention provides a crystalline form compound of male-3,5?,6?-triol (hereinafter referred to as twin crystal form YC-6), characterized in that the crystalline form compound is a transparent needle crystal.
• twin crystal form YC-6 a crystalline form compound of male-3,5?,6?-triol
• the crystalline form compound is a transparent needle crystal.
• the preparation method of the B crystal form YC-6 provided by the invention is: dissolving androst-3 ⁇ ,5 ⁇ ,6 ⁇ -triol in a solvent, androst-3 ⁇ ,5 ⁇ ,6 ⁇ -triol and a solvent
• the ratio is lg: 10 to 120 ml, heated to 50 to 80 ° C, diluted with a solvent, cooled, and allowed to stand until crystals are precipitated.
• the solvent used for the dissolution is acetone, ethyl acetate or ethanol;
• the solvent used for the dilution is a raw solvent or a poor solvent, wherein the raw solvent is acetone, ethyl acetate or Ethanol, the poor solvent is water, cyclohexane or petroleum ether.
• the dilution ratio When acetone or ethanol is used as a dissolution solvent and diluted with a poor solvent water, the dilution ratio is 2.5 to 5 times; when acetone or ethanol is used as a dissolution solvent, and diluted with a poor solvent cyclohexane or petroleum ether, the dilution ratio is 1 ⁇ 5 times; when ethyl acetate is used as a dissolving solvent and diluted with ethyl acetate as a raw solvent, the dilution ratio is 0 to 5 times; when ethyl acetate is used as a dissolution solvent, and diluted with a poor solvent such as cyclohexane or petroleum ether, The dilution ratio is 0 to 5 times.
• the present invention provides a crystalline form compound of male-3,5?,6?-triol (hereinafter referred to as C crystal form YC-6), characterized in that the crystalline form compound is a transparent plate crystal.
• C crystal form YC-6 a crystalline form compound of male-3,5?,6?-triol
• the crystalline form compound is a transparent plate crystal.
• the preparation method of the C crystal form YC-6 provided by the invention is as follows: the male ⁇ -3 ⁇ ,5 ⁇ ,6 ⁇ -triol is dissolved in ethanol at room temperature, androst-3 ⁇ ,5 ⁇ ,6 ⁇ -three The ratio of alcohol to ethanol is lg: 10 ⁇ 30ml, and then diluted with 0-5 times ethanol, and crystals are precipitated at 0-10 °C.
• the invention provides a crystalline compound of male ⁇ -3 ⁇ ,5 ⁇ ,6 ⁇ -triol (hereinafter referred to as D crystal form)
• the preparation method of the D crystal form YC-6 provided by the invention is as follows: the male ⁇ -3 ⁇ ,5 a,6 ⁇ -triol is dissolved in tetrahydrofuran at room temperature, and the male ⁇ -3 ⁇ ,5 a,6 ⁇ -three
• the ratio of alcohol to tetrahydrofuran was lg: 10 to 30 ml, and then diluted with 0-5 times of tetrahydrofuran, and allowed to stand until crystals were precipitated.
• the present invention provides four crystal form compounds of androst-3 ⁇ ,5 a,6 ⁇ -triol (ie, the crystalline form YC-6, B crystalline form YC-6, C crystalline form YC-6, D crystalline form
• the characteristics of YC-6) are that there are significant differences in their unit cell parameters, X-ray powder diffraction, and the parameters such as intensity and melting point.
• the polymorphism is studied to further study its efficacy, bioavailability and stability. It is of great significance.
• Figure 1 is an X-ray single crystal diffraction pattern of Form A YC-6;
• Figure 2 is an X-ray powder diffraction pattern of Form A YC-6;
• Figure 3 is a differential thermal analysis diagram of Form A YC-6;
• Figure 4 is an X-ray single crystal diffraction pattern of B crystal form YC-6;
• Figure 5 is an X-ray powder diffraction pattern of B crystal form YC-6;
• Figure 6 is a differential thermal analysis diagram of B crystal form YC-6;
• Figure 7 is an X-ray single crystal diffraction pattern of C crystal form YC-6;
• Figure 8 is an X-ray powder diffraction pattern of Form C YC-6;
• Figure 9 is a differential thermal analysis diagram of Form C YC-6;
• Figure 10 is an X-ray single crystal diffraction pattern of D crystal form YC-6;
• Figure 11 is an X-ray powder diffraction pattern of Form D YC-6;
• Fig. 12 is a differential thermal analysis diagram of the D crystal form YC-6. detailed description
• the X-ray single crystal diffraction pattern of different crystal forms YC_6 obtained in the measurement examples of Technologies (China) Co., Ltd. was as follows: copper fixed target, output power 50 W, two-dimensional surface inspection system: 165 mm CCD, resolution 0005 degrees, cooled nitrogen, -180 ⁇ +25°C, control accuracy ⁇ ⁇ 0.5°C, test temperature is 150k.
• the X-ray powder diffraction patterns of the different crystal forms YC-6 obtained in the examples were measured by D/Max-IIIA (Japanese physics) X-ray powder diffractometer, and the measurement conditions were as follows: copper fixed target, power 3 kW, angle range 1 ⁇ 50°, sensitivity is 3 ⁇ 5%, angle measurement accuracy is ⁇ 0.002.
• the single crystal diffraction, powder diffraction and DSC analysis parameters of the four crystal forms YC-6 are as follows:
• the twin crystal type YC-6 has a diffraction angle of 2 ⁇ of 4.4 ⁇ 0.1, 8.7 ⁇ 0.1, 9.3 ⁇ 0.1, 12.6 ⁇ 0.1, 13.0.
• the differential scanning thermogram (DSC) of the twin crystal YC-6 is shown in Figure 3, and its endothermic transition temperature is 225 ⁇ 2 °C.
• the twin crystal YC-6 has a diffraction angle of 2 ⁇ of 4.3 ⁇ 0.1, 8.6 ⁇ 0.1, 12.9 ⁇ 0.1, 17.2 ⁇ 0.1, There is a diffraction peak at 21.6 ⁇ 0.1 degrees, and the X-ray powder diffraction pattern is shown in Fig. 5.
• the differential scanning calorimetry chart (DSC) of the B crystal form YC-6 has an endothermic transition temperature of 223 ⁇ 2 °C as shown in Fig. 6.
• the crystal form YC-6 has a diffraction angle of 2 ⁇ of 4.2 ⁇ 0.1, 8.5 ⁇ 0.1, 9.0 ⁇ 0.1, 12.5 ⁇ 0.1, 14.8 ⁇ 0.1, 15.4 ⁇ 0.1, 16.4 ⁇ 0.1, 16.8 ⁇ 0.2, 17.1 ⁇ 0.1, 18.3 ⁇
• DSC Differential Scanning Thermal Analysis
• D crystal form YC-6 at diffraction angle 2 ⁇ is 4.0 ⁇ 0.1, 8.1 ⁇ 0.1, 8.5 ⁇ 0.1, 9.4 ⁇ 0.1, 12.5
• D-Form YC-6 Differential Scanning Thermal Analysis As shown in Figure 12, the endothermic transition temperature is 226 ⁇ 2 °C.
• YC-6 0.5 g of YC-6 was dissolved in 8 ml of acetone at 50-60 ° C, diluted with 1 time of acetone, and allowed to stand until crystals were precipitated. The obtained single crystal was directly subjected to X-ray single crystal diffraction, and the crystal was filtered, dried at 60 ° C to constant weight, and subjected to X-ray powder diffraction and differential scanning calorimetry.
• YC-6 0.5 g of YC-6 was dissolved in 10 ml of acetone at room temperature, diluted with 1 time of acetone, and allowed to stand until crystals were precipitated. The obtained single crystal was directly subjected to X-ray single crystal diffraction, and the crystal was filtered, dried at 60 ° C to constant weight, and subjected to X-ray powder diffraction and differential scanning calorimetry.
• Example 3 Preparation of Form A YC-6: 0.5 g of YC-6 was dissolved in 7 ml of ethanol at room temperature, diluted with 1 time of ethanol, and allowed to stand until crystals were precipitated. The obtained single crystal was directly subjected to X-ray single crystal diffraction, and the crystal was suction-filtered, dried at 60 ° C to constant weight, and subjected to X-ray powder diffraction and differential scanning calorimetry.
• YC-6 0.5 g of YC-6 was dissolved in 12 ml of acetone at room temperature, diluted with one-fifth of acetone, and allowed to stand until crystals were precipitated. The obtained single crystal was directly subjected to X-ray single crystal diffraction, and the crystal was suction-filtered, dried at 60 ° C to constant weight, and subjected to X-ray powder diffraction and differential scanning calorimetry.
• YC-6 0.5 g of YC-6 was dissolved in 10 ml of ethanol at room temperature, and then diluted with water in an amount of one-half of ethanol, and allowed to stand until crystals were precipitated. The obtained single crystal was directly subjected to X-ray single crystal diffraction, and the crystal was suction-filtered, dried at 60 ° C to constant weight, and subjected to X-ray powder diffraction and differential scanning calorimetry.
• the X-ray single crystal diffraction unit cell parameters in the test examples 1-5 were the same, and the obtained crystals were all the A crystal form YC_6.
• Form B YC-6 0.5 g of YC-6 was dissolved in 8 ml of acetone, heated to 50-60 ° C, diluted with 24 ml of water, cooled, and allowed to stand until crystals were precipitated. The obtained single crystal was directly subjected to X-ray single crystal diffraction, and the crystal was suction-filtered, dried at 70 ° C to constant weight, and subjected to X-ray powder diffraction and differential scanning calorimetry.
• Example 9 Preparation of Form B YC-6: 0.5 g of YC-6 was dissolved in 12 ml of acetone, heated to 50-60 ° C, diluted with 36 ml of cyclohexane, cooled, and allowed to stand until crystals were precipitated. The obtained single crystal was directly subjected to X-ray single crystal diffraction, and the crystal was suction-filtered, dried at 70 ° C to constant weight, and subjected to X-ray powder diffraction and differential scanning calorimetry.
• the X-ray single crystal diffraction unit cell parameters in the test examples 6-9 were the same, and the obtained crystals were both B crystal form YC_6.
• Form C YC-6 0.5 g of YC-6 was dissolved in 12 ml of ethanol at room temperature, diluted with 1 times of ethanol, and placed at 10 ° C for crystallization. The obtained single crystal was directly subjected to X-ray single crystal diffraction. The crystal was suction filtered, dried at 70 ° C to constant weight, and subjected to X-ray powder diffraction and differential scanning calorimetry.
• Form C YC-6 Dissolve 0.5 g of YC-6 in 15 ml of ethanol at room temperature, dilute with 1 time of ethanol, and crystallize at 10 ° C. The obtained single crystal is directly subjected to X-ray single crystal diffraction. The crystal was suction filtered, dried at 70 ° C to constant weight, and subjected to X-ray powder diffraction and differential scanning calorimetry.
• Form C YC-6 Dissolve 0.5 g of YC-6 in 15 ml of ethanol at room temperature, dilute with 2 times the amount of ethanol, and place the crystal at 10 ° C. The obtained single crystal is directly subjected to X-ray single crystal diffraction. The crystal was suction filtered, dried at 70 ° C to constant weight, and subjected to X-ray powder diffraction and differential scanning calorimetry.
• the X-ray single crystal diffraction unit cell parameters in the test examples 10-12 were the same, and the obtained crystals were all C crystal form YC_6.
• D crystal form YC-6 Dissolve 0.5 g of YC-6 in 10 ml of tetrahydrofuran at room temperature, dilute with 1 time of tetrahydrofuran, and let stand until crystals are precipitated. The obtained single crystal is directly subjected to X-ray single crystal diffraction. The crystals were suction filtered, dried at 70 ° C to constant weight, and subjected to X-ray powder diffraction and differential scanning calorimetry.
• Form D YC-6 0.5 g of YC-6 was dissolved in 10 ml of tetrahydrofuran at room temperature, diluted with 2 times the amount of tetrahydrofuran, and allowed to stand until crystals were precipitated. The obtained single crystal was directly subjected to X-ray single crystal diffraction, and the crystal was suction-filtered, dried at 70 ° C to constant weight, and subjected to X-ray powder diffraction and differential scanning calorimetry.
• Example 15 Preparation of Form D YC-6: 0.5 g of YC-6 was dissolved in 15 ml of tetrahydrofuran at room temperature, and then diluted with 1 time of tetrahydrofuran, and allowed to stand until crystals were precipitated. The obtained single crystal was directly subjected to X-ray single crystal diffraction, and the crystal was suction-filtered, dried at 70 ° C to constant weight, and subjected to X-ray powder diffraction and differential scanning calorimetry.
• the X-ray single crystal diffraction unit cell parameters in the test examples 13-15 were the same, and the obtained crystals were all D crystal form YC-6.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Steroid Compounds (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Related Child Applications (3)

Publications (1)

Family

ID=46557937

Family Applications (1)

Country Status (13)

Families Citing this family (3)

Citations (3)

Family Cites Families (4)

• 2012
  • 2012-03-08 CN CN201310392426.1A patent/CN103626817B/zh active Active
  • 2012-03-08 CN CN201210060611.6A patent/CN102617685B/zh active Active
  • 2012-03-08 CN CN201310393373.5A patent/CN103626819B/zh active Active
  • 2012-03-08 CN CN201310393026.2A patent/CN103626818B/zh active Active
  • 2012-04-11 IN IN8198DEN2014 patent/IN2014DN08198A/en unknown
  • 2012-04-11 US US14/383,405 patent/US9688716B2/en active Active
  • 2012-04-11 WO PCT/CN2012/073854 patent/WO2013131305A1/zh not_active Ceased
  • 2012-04-11 CA CA2909998A patent/CA2909998A1/en not_active Abandoned
  • 2012-04-11 KR KR1020147028362A patent/KR20150002653A/ko not_active Ceased
  • 2012-04-11 SG SG11201405376TA patent/SG11201405376TA/en unknown
  • 2012-04-11 EP EP12870566.2A patent/EP2889303A4/en not_active Withdrawn
  • 2012-04-11 RU RU2014136891A patent/RU2608894C2/ru active
  • 2012-04-11 JP JP2014560211A patent/JP2015511587A/ja active Pending
  • 2012-04-11 AU AU2012372640A patent/AU2012372640B2/en active Active
  • 2012-04-11 CA CA2866398A patent/CA2866398C/en active Active
  • 2012-04-11 EP EP16184231.5A patent/EP3112374A1/en not_active Ceased
• 2013
  • 2013-03-07 TW TW102108093A patent/TW201336861A/zh unknown
• 2014
  • 2014-09-07 IL IL234492A patent/IL234492A/en active IP Right Grant
• 2017
  • 2017-05-08 US US15/589,268 patent/US9944673B2/en active Active
  • 2017-05-08 US US15/589,228 patent/US9944672B2/en active Active

Patent Citations (3)

Also Published As

Similar Documents

Legal Events